Mid‐dosing interval concentration is important for polymyxin B exposure and acute kidney injury in critically ill patients
Open Access
- 17 September 2023
- journal article
- research article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 12 (12) , 1911-1921
Abstract
This study aimed to evaluate the association between polymyxin B (PMB) exposure and acute kidney injury (AKI) and analyze the risk factors for PMB‐induced AKI in critically ill patients. Plasma concentrations of PMB were determined using an ultraperformance liquid chromatography–tandem mass spectrometer in intensive care unit patients who were administered PMB. Univariate and multivariate analyses were conducted to identify risk factors. A receiver operating characteristic curve was constructed to assess the discriminant power of the factors and to identify the cutoff value for AKI. The white blood cell count and estimated area under the concentration–time curve (AUC) of patients administered PMB were independent risk factors for PMB‐induced AKI, where AUC were calculated using a first‐order pharmacokinetic equation based on the mid‐dosing interval concentration (C1/2t) and peak concentration. The area under the receiver operating characteristic curve of the final model was 0.805 (95% confidence interval, 0.690–0.921). The cutoff value for the combined predictor was 0.57. Alternatively, when using C1/2t, which was strongly correlated with AUC, as the only independent risk factor, the analysis showed that the 3.47 μg/ml threshold provides favorable differentiation between the AKI and non‐AKI groups. These results provide insightful information for therapeutic drug monitoring–guiding PMB dosing in clinical practice.Keywords
This publication has 31 references indexed in Scilit:
- Uptake of Polymyxin B into Renal CellsAntimicrobial Agents and Chemotherapy, 2014
- Colistin and Polymyxin B: Peas in a Pod, or Chalk and Cheese?Clinical Infectious Diseases, 2014
- Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodiumInternational Journal of Antimicrobial Agents, 2014
- To study the clinical efficacy and nephrotoxicity along with the risk factors for acute kidney injury associated with parenteral polymyxin BIndian Journal of Critical Care Medicine, 2013
- Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapyJournal of Infection, 2012
- Effectiveness and Tolerability of A Polymyxin B Dosing ProtocolAnnals of Pharmacotherapy, 2012
- The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibioticJournal of Antimicrobial Chemotherapy, 2010
- Prevalence and Risk Factors for Acute Kidney Injury Associated with Parenteral Polymyxin B UseAnnals of Pharmacotherapy, 2009
- Multinomial goodness‐of‐fit tests for logistic regression modelsStatistics in Medicine, 2008
- Polymyxin B Nephrotoxicity and Efficacy against Nosocomial Infections Caused by Multiresistant Gram-Negative BacteriaAntimicrobial Agents and Chemotherapy, 2003